Zacks Research Issues Pessimistic Outlook for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Investment analysts at Zacks Research lowered their Q2 2026 earnings per share (EPS) estimates for shares of Agilent Technologies in a research report issued to clients and investors on Monday, February 24th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $1.46 for the quarter, down from their previous estimate of $1.47. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%.

A has been the topic of several other reports. Sanford C. Bernstein dropped their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Barclays upgraded Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Bank of America dropped their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Citigroup lifted their price objective on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Finally, StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and an average price target of $144.38.

Agilent Technologies Stock Performance

Shares of NYSE:A opened at $134.51 on Thursday. The company has a market cap of $38.37 billion, a P/E ratio of 30.43, a PEG ratio of 3.63 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. Agilent Technologies has a one year low of $124.16 and a one year high of $155.35. The business’s 50-day simple moving average is $140.90 and its 200 day simple moving average is $139.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in A. Flynn Zito Capital Management LLC boosted its position in Agilent Technologies by 3.8% during the 4th quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company’s stock worth $251,000 after acquiring an additional 69 shares during the period. IFP Advisors Inc raised its stake in shares of Agilent Technologies by 17.7% in the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock worth $62,000 after buying an additional 69 shares in the last quarter. Tiemann Investment Advisors LLC raised its stake in shares of Agilent Technologies by 5.6% in the 4th quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company’s stock worth $191,000 after buying an additional 75 shares in the last quarter. Brown Brothers Harriman & Co. raised its stake in shares of Agilent Technologies by 13.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after buying an additional 77 shares in the last quarter. Finally, Rothschild Investment LLC raised its stake in shares of Agilent Technologies by 19.2% in the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock worth $66,000 after buying an additional 79 shares in the last quarter.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now owns 39,652 shares in the company, valued at $5,947,800. The trade was a 4.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.74%. Agilent Technologies’s dividend payout ratio is currently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.